LA
JOLLA, Calif., Sept. 6,
2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer,
will participate in a presentation at the H.C. Wainwright 25th
Annual Global Investment Conference on Wednesday, September 13, 2023, at 1:30 p.m. – 2:00 p.m.
ET/ 10:30 a.m. – 11 a.m. PT.
The Company will also be hosting a virtual Acute Pancreatitis
Clinical Experts Event on Thursday,
September 21, 2023, from 10:30
a.m. – 12 p.m. ET/
7:30 a.m. – 9
a.m. PT featuring Joseph
Miller, M.D., Clinical Associate Professor of Emergency
Medicine at Henry Ford Health and Michigan
State University and Associate Director of Emergency Care
Research at Henry Ford Health, and Georgios
Papachristou, M.D., Ph.D., Professor of Medicine, Floyd
Beman Endowed Chair in Gastroenterology and division director for
Gastroenterology, Hepatology and Nutrition at The Ohio State University College of Medicine.
Webcast Information
Live webcasts of both events, as
well as registration for the clinical experts event, can be
accessed in the "Upcoming Events" section of CalciMedica's IR
website at https://ir.calcimedica.com/. A replay of the Acute
Pancreatitis Clinical Experts Event will be available for one year
following the completion of the event, and a replay of the
conference presentation will be available for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels designed to modulate the immune response and protect
against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™, a
proprietary, intravenous-formulated CRAC channel inhibitor, has
demonstrated positive and consistent clinical results in multiple
completed efficacy clinical trials. Auxora is in development for AP
with SIRS and AIPT. CalciMedica was founded by scientists from
Torrey Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla, CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-presentations-and-events-in-september-301918721.html
SOURCE CalciMedica